Several anesthetic agents beyond ketamine show antidepressant effects, including nitrous oxide, propofol, isoflurane, sevoflurane, dexmedetomidine, and xenon. This review examines clinical and basic science studies on these anesthetics for treating depression. The authors propose that anesthetics may alleviate depression by modulating brain dynamics that alter arousal states, linking anesthetic mechanisms to depression pathophysiology and findings from other treatments. The work suggests that repurposing anesthetics could offer new options for major depressive disorder and treatment-resistant depression.
Dexmedetomidine (DEX) is a sedative that produces a sleep-like state and offers a way to study shifts in consciousness using behavior, EEG, and TMS-evoked EEG responses. Little is known about how repeated DEX exposure affects recovery. This pilot trial plans to sedate 12 healthy volunteers twice, one week apart, monitoring responsiveness with an auditory click task. It will compare time to return of responsiveness between visits, explore sex differences, and assess state transitions via EEG signatures, TMS-evoked complexity, and cognitive tests. The study also evaluates the feasibility of TMS-EEG during DEX sedation and reports on sleep quality and experiences.